宝济药业-B（上海宝济药业股份有限公司，股票代码：02659）于2026年7月27日发布公告，称公司当日于香港联交所回购H股70,600股，占该次回购前已发行股本的约0.04623%，每股回购价介乎17.47港元至18.54港元，合计支付约128.49万港元。
公告显示，此次回购完成后，公司已发行股本减少至152,657,450股，库藏股数量增至1,669,800股，总股本仍为154,327,250股。根据此前于2026年5月26日通过的购回授权，宝济药业-B最多可回购15,432,725股股份，截至目前已合计回购1,669,800股。公司强调，此次交易已获董事会批准并符合香港联交所证券上市规则及相关法律法规。此外，本次回购后，如无特别批准，公司在2026年8月26日之前不会进行新的股份发行或库藏股出售。公告由执行董事刘彦君签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.